BRIEF-Biotest regains rights to Tregalizumab (BT-061)
June 24, 2015 at 03:18 AM EDT
* AbbVie exercised its rights to opt-out of worldwide license, development and commercialisation agreement
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.